Posts by: Ines Martins, PhD

Ines Martins, PhD

Inês Martins holds a BSc in Cell and Molecular Biology from Universidade Nova de Lisboa and is currently finishing her PhD in Biomedical Sciences at Universidade de Lisboa. Her work has been focused on blood vessels and their role in both hematopoiesis and cancer development.

June 2, 2017June 6, 2017

Triple Immunotherapy Combo to Be Tested in Trial with Bladder Cancer Patients

News

Two immunotherapies, INO–5401 and INO–9012, will be combined with immune checkpoint inhibitor Tecentriq (atezolizumab) in a Phase 1/2 trial to test the combo’s safety and effectiveness in treating advanced ... Read more

June 1, 2017

Intensity’s Treatment Candidate Administered to First Solid Tumor Patient in Phase 1/2 Trial

News

The first patient has successfully received treatment in a Phase 1/2 trial evaluating Intensity Therapeutics‘ drug candidate INT230-6 in different types of advanced solid tumors. The study will enroll ... Read more

May 31, 2017

First Patient Dosed in Phase 2 Portion of Trial of X4P-001 Combo for Kidney Cancer

News

Researchers have dosed the first patient in the second part of a combined-phase clinical trial evaluating a combination of X4P-001 and Inlyta (axitinib) as a treatment for advanced kidney cancer. The ... Read more

May 25, 2017May 25, 2017

FDA Chalks Up a First by Approving Keytruda for Cancers with Specific Genetic Features

News

In a first, the U.S. Food and Drug Administration has approved a treatment for cancer patients with specific genetic features in their tumors rather than a specific tumor type. ... Read more

May 24, 2017

FDA Grants Priority Review to Keytruda for Heavily-treated Stomach Cancer Patients

News

The U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics Licence Application (sBLA) seeking approval for Keytruda (pembrolizumab) to treat patients with recurrent or advanced ... Read more

May 23, 2017

Nanoparticle Shows Promise in Engaging Immune System to Fight Tumors

News

The radio-enhancer nanoparticle NBTXR3, which is being developed to treat seven types of cancer, can effectively engage patients’ immune systems to fight cancer, transforming “cold” tumors into “hot” tumors. ... Read more

May 19, 2017May 19, 2017

Progenitor Develops 2 New Gene Editing Tools to Improve Off-the-Shelf Cellular Immunotherapies

News

Progenitor Life Sciences, a company that specializes in developing off-the-shelf cellular immunotherapies, has developed two additional technologies that will improve immune cell engineering and production in future immunotherapy approaches. ... Read more

May 17, 2017

OSE-172 Continues to Show Promising Activity Against Multiple Cancer Models, Researchers Say

News

A new-generation checkpoint inhibitor, OSE-172 (Effi-DEM), targeting myeloid derived suppressor cells (MDSCs) and tumor associated macrophages (TAMs), can effectively modify the tumor environment and lead to the intra-tumoral accumulation of ... Read more

May 15, 2017May 15, 2017

NantKwest, NantCell to Test NANT Vaccine in Phase 1/2 Trial for Pancreatic Cancer Patients

News

The U.S. Food and Drug Administration (FDA) has granted investigational new drug status to the NANT cancer vaccine, to be assessed in a Phase 1/2 clinical trial (NCT03136406) for ... Read more

May 12, 2017

Tecentriq Fails to Improve Survival in Previously Treated Metastatic Bladder Cancer Patients in Phase 3 Study

News

The immune checkpoint inhibitor Tecentriq (atezolizumab) failed to improve overall survival in a subset of patients with locally advanced or metastatic urothelial cancer (mUC). The findings mean that Genentech‘s ... Read more